Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-500-6
CAS number: 96-33-3
In a subchronic study in Sprague-Dawley rats following vapour inhalation for 12-weeks, the NOAEC was 82 mg/m3. The respective LOAEC based on reduced body weight and reduced organ weights was 440 mg/m3. Following chronic exposure by the inhalation route (5 d/w, 6 h/d), the LOAEC for local effects (nasal and ocular) in rats was 58 mg/m3. The systemic NOAEC was >= 519 mg/m3. Following a 90-day oral administration of MA in the drinking water, the NOAEL was 5 mg/kg bw/d for CDF Fischer 344 rats. The LOAEL was 20 mg/kg bw/day based on changes in kidney weights.
dose toxicity: Inhalation:
Sprague Dawley rats/sex/group were exposed to 23, 124, 242 and 626 ppm;
(0.082, 0.44, 0.86 and 2.24 mg/L) for 12 weeks, 5 day a week, 6 hours
per day. The No Observed Adverse Effect Concentration (NOAEC) was 23 ppm
(0.082 mg/L) (no clinical/chemical/haematological effect, no effect on
body weight, organ weight and histology) and the Lowest Observed Adverse
Effect Concentration (LOAEC) was 124 ppm (0.44 mg/L) (reduced body
weight, reduced organ weights). At 242 ppm (0.860 mg/L), methyl acrylate
caused transient respiratory and eye irritation at the beginning of
exposure. At 626 ppm (2.24 mg/L), the animals exhibited laboured
breathing, irritation of the mucosa, and hemorrhagic discharge from the
eyes and nose that became increasingly severe. All animals of this dose
group died during the first half of the study due to strong irritation
(hyperemia in the trachea and lungs along with bronchopneumonia).
Reduced body weight gain was seen to be treatment related in the 124-626
ppm groups (0.440 –2.24 mg/L). Increased relative lung and relative
liver weights were observed in the 242 ppm group, and in the females of
the 124 ppm group without detectable microscopic changes in these
organs. Absolute organ weights of heart, liver, kidney and spleen were
decreased in males of the 242 ppm dose group, absolute spleen weight of
males was also reduced in the 124 ppm group. Keratinisation of the
transition epithelium between respiratory and olfactory epithelium was
observed, as well as degeneration and vacuolization of the olfactory
epithelium at the histological examination of the 242 ppm and 626 ppm
groups, but not in the 124 ppm group. No changes in blood chemistry were
found, apart from a rise in sodium values and a drop in potassium values
in the 242 ppm group (the 626 ppm group was not evaluated for blood
chemistry due to lethality) (BASF AG 1978, 1980).
a 2 year inhalation study rats were exposed 5 days/week, 6 hours/day to
concentrations of 0, 5, 15, 45 ppm (0, 0.019, 0.058, 0.173 mg/L) during
the first 13 weeks; followed by 0, 15, 45, 135 ppm (0, 0.058, 0.173,
0.519 mg/L) until the end of the study. Irritative changes, atrophy and
basal cell hyperplasia in the nasal passage, accompanied by loss of
olfactory and ciliated cells of the nasal turbinates, were observed when
rats were exposed up to 135 ppm (0.519 mg/L) for 2 years (BASF AG 1985,
Reininghaus 1991). Histological changes in the nasal mucosa were dose
dependent; and were described as slight degeneration of the olfactory
epithelium at 15 ppm, and partial loss of the columar cell layer and
stratified reserve-cell hyperplasia at 45 and 135 ppm. Males and females
were affected in the same manner. No changes were detected in the
posterior nasal cavity, and no irritative effects on the larynx, trachea
or lungs were seen. Opacification and vascularisation of the cornea were
observed in all exposed animals. The only systemic changes observed were
a slight and reversible delay in body weight gains along with changes in
organ weights without histological correlation (mainly in the highest
dose group.) There were no treatment related increases in benign or
malignant tumours. The Lowest Observed Adverse Effect Concentration
(LOAEC) for contact effects (nasal and ocular) was 15 ppm (0.058 mg/L).
(For more details see Section Carcinogenicity)
dose toxicity: Oral:
a 3-month oral administration of methyl acrylate to the F344 rat in
drinking water (0; 1, 5 and 20 mg/kg bw/d) slight decreases in body
weight gain and water consumption were noted in both sexes receiving the
highest dose. Also observed in the female rats at the highest dose was
an increase in urinary specific gravity, probably as a result of
decreased water intake and a slight but statistically significant
increase in the mean relative kidney weight. All alterations seen in
histology were typical of those occurring spontaneously in rats of this
age and strain. The kidneys of male rats at the highest dose showed an
increase in severity of a spontaneous renal disease normally seen in
F344 rats. This alteration characterized by dilated renal tubules and
eosinophilic cast formation, was observed in six of 10 males examined
from the 20 mg/kg bw/day dose and in two of 10 male controls.
observation was also noted in 2 of 10 females at the highest dose and in
none of the female controls. The increase in relative organ weights and
the histopathological observations indicate that the highest dose may
have had a slight effect on the kidneys. No other histopathological
effects were seen, including the sex organs. The No Observed Adverse
Effect Level (NOAEL) based on the effects seen at 20 mg/kg bw/day in
this study was determined to be 5 mg/kg bw/day for male and female CDF
Fischer 344 rats and the Lowest Observed Adverse Effect Level was 20
mg/kg bw/day (Dow 1981).
dose toxicity: Dermal:
subacute or subchronic repeated dose studies with dermal application are
available for Methyl acrylate.
EU classification according to Regulation (EC) No. 1272/2008:
- Specific Target Organ Toxicity: Repeated Exposure: no classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again